Literature DB >> 22438228

Adiponectin as an independent predictor of the presence and degree of hepatic steatosis in the Dallas Heart Study.

Aslan T Turer1, Jeffrey D Browning, Colby R Ayers, Sandeep R Das, Amit Khera, Gloria L Vega, Scott M Grundy, Philipp E Scherer.   

Abstract

CONTEXT: Previous small case-control studies have suggested an inverse relationship between adiponectin and hepatic steatosis, but whether this finding is independent of insulin sensitivity and other intraabdominal fat depots is unclear. OBJECTIVES AND MAIN OUTCOME MEASURES: The objective of this study was to establish whether an independent relationship exists between serum adiponectin concentrations and liver fat. DESIGN, SETTING, AND PATIENTS: Adiponectin levels were compared with hepatic triglyceride content (HTGC) as assessed by proton magnetic resonance spectroscopy in 2215 participants from the Dallas Heart Study. Multivariate modeling was performed to control for the effects of intraabdominal fat, insulin sensitivity, and other baseline factors.
RESULTS: In unadjusted analysis, adiponectin levels displayed inverse correlations with the amount of intraabdominal fat and HTGC. After multivariate adjustment, including individual intraabdominal fat depots and homeostasis model assessment of insulin resistance, HTGC remained significantly associated with adiponectin levels (β = -1.46, P < 0.0001 for women; β = -1.81, P < 0.0001 for men). Race- and gender-specific models demonstrated that this association was consistent across groups, except for Hispanic men. The adjusted odds ratio for hepatic steatosis (HTGC > 5.5%) per 1-sd increase in adiponectin concentrations was 0.64 (95% confidence interval = 0.52-0.78) for women and 0.61 (95% confidence interval = 0.51-0.74) for men.
CONCLUSION: Data from a large, multiethnic population-based cohort show adiponectin levels are inversely associated with hepatic steatosis even after controlling for measures of insulin sensitivity, extrahepatic abdominal adiposity, and ethnicity. The mechanistic underpinnings of this association warrant further exploration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438228     DOI: 10.1210/jc.2011-3305

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation.

Authors:  Birju D Bhatt; Thresiamma Lukose; Abby B Siegel; Robert S Brown; Elizabeth C Verna
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 2.  Adiponectin: a key playmaker adipocytokine in non-alcoholic fatty liver disease.

Authors:  Nikolaos K Gatselis; George Ntaios; Konstantinos Makaritsis; George N Dalekos
Journal:  Clin Exp Med       Date:  2013-01-05       Impact factor: 3.984

3.  Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.

Authors:  Veeral Ajmera; Emily R Perito; Nathan M Bass; Norah A Terrault; Katherine P Yates; Ryan Gill; Rohit Loomba; Anna Mae Diehl; Bradley E Aouizerat
Journal:  Hepatology       Date:  2016-10-12       Impact factor: 17.425

Review 4.  Metabolic control and sex: A focus on inflammatory-linked mediators.

Authors:  Darren C Henstridge; Julie Abildgaard; Birgitte Lindegaard; Mark A Febbraio
Journal:  Br J Pharmacol       Date:  2019-04-21       Impact factor: 8.739

5.  Targeted Induction of Ceramide Degradation Leads to Improved Systemic Metabolism and Reduced Hepatic Steatosis.

Authors:  Jonathan Y Xia; William L Holland; Christine M Kusminski; Kai Sun; Ankit X Sharma; Mackenzie J Pearson; Angelika J Sifuentes; Jeffrey G McDonald; Ruth Gordillo; Philipp E Scherer
Journal:  Cell Metab       Date:  2015-07-16       Impact factor: 27.287

Review 6.  Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis.

Authors:  Ryutaro Kuraji; Satoshi Sekino; Yvonne Kapila; Yukihiro Numabe
Journal:  Periodontol 2000       Date:  2021-10       Impact factor: 7.589

Review 7.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

8.  Improved hepatic lipid composition following short-term exercise in nonalcoholic fatty liver disease.

Authors:  Jacob M Haus; Thomas P J Solomon; Karen R Kelly; Ciaran E Fealy; Emily L Kullman; Amanda R Scelsi; Lan Lu; Mangesh R Pagadala; Arthur J McCullough; Chris A Flask; John P Kirwan
Journal:  J Clin Endocrinol Metab       Date:  2013-04-24       Impact factor: 5.958

Review 9.  Low-normal thyroid function and novel cardiometabolic biomarkers.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Nutrients       Date:  2015-02-16       Impact factor: 5.717

10.  Predicting total, abdominal, visceral and hepatic adiposity with circulating biomarkers in Caucasian and Japanese American women.

Authors:  Unhee Lim; Stephen D Turner; Adrian A Franke; Robert V Cooney; Lynne R Wilkens; Thomas Ernst; Cheryl L Albright; Rachel Novotny; Linda Chang; Laurence N Kolonel; Suzanne P Murphy; Loïc Le Marchand
Journal:  PLoS One       Date:  2012-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.